Resultados de Búsqueda

Evidencias COVID-19

Evidence Aid

No serious adverse events were reported for treatment with mesenchymal stromal cells and all minor adverse events related to mesenchymal stromal cell treatment resolved spontaneously.

Evidencias COVID-19

Cochrane - Revisión sistemática

Quarantine of people exposed to confirmed or suspected cases prevented between 44% and 81% of incident cases and between 31% and 63% of deaths, compared to no measure, according to different scenarios (incident cases: four modeling studies on COVID-19, SARS; mortality: two modeling studies on COVID-19, SARS, low-certainty evidence)

Evidencias COVID-19

CEBM

Data suggest that the harms from using the 4-aminoquinolines, chloroquine and hydroxychloroquine, to treat established covid-19 outweigh their benefits and that there is no benefit in post-exposure prophylaxis

Evidencias COVID-19

CEBM

Patients with severe COVID-19 can develop cytokine release syndrome (“cytokine storm”) and are reported to have high circulating IL-6 concentrations. Tocilizumab is a recombinant humanized anti-human IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R). It has therefore been proposed to be of value in the management of severe COVID-19. Serious and sometimes fatal infections have been reported. The manufacturer therefore recommends that treatment should not be started ...

Prescrire bilan. Towards better patient care: drugs to avoid

Prescrire International

It can cause serious and even life-threatening cardiovas- cular disorders (hypertensive crisis, stroke, and arrhythmias, including atrial fibrillation), as well as ischaemic colitis. These adverse effects are unac- ceptable for drugs indicated for minor, rapidly self-resolving symptoms such as those associated with the common cold